WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/093125    International Application No.:    PCT/EP2012/050061
Publication Date: 12.07.2012 International Filing Date: 04.01.2012
C07K 16/28 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; 980 Great West Road Brentford Middlesex TW8 9GS (GB) (For All Designated States Except US).
BEATON, Andrew [GB/GB]; (GB) (For US Only).
DIMECH, Caroline [GB/GB]; (GB) (For US Only).
ERTL, Peter, Franz [GB/GB]; (GB) (For US Only).
FORD, Susannah, Karen [GB/GB]; (GB) (For US Only).
MCADAM, Ruth [GB/GB]; (GB) (For US Only)
Inventors: BEATON, Andrew; (GB).
DIMECH, Caroline; (GB).
ERTL, Peter, Franz; (GB).
FORD, Susannah, Karen; (GB).
MCADAM, Ruth; (GB)
Agent: HARRISON, Anna; GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford Middlesex TW8 9GS (GB)
Priority Data:
61/430,235 06.01.2011 US
Abstract: front page image
(EN)The disclosure provides an anti -TGFbetaRII immunoglobulin single variable domain. Suitably, an anti -TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO: 1-38, 204, 206, 208, 214, 234, 236, 238, 240, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289 or 291 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
(FR)L'invention concerne un domaine variable unique d'immunoglobuline anti-TGFbêtaRII. Le domaine selon l'invention contient une séquence d'acides aminés telle que présentée dans SEQ ID NO: 1-38, 204, 206, 208, 214, 234, 236, 238, 240, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289 ou 291, contenant jusqu'à 5 substitutions, délétions ou additions d'acides aminés. L'invention concerne également un polypeptide et une composition pharmaceutique destinés à traiter une maladie associée à la signalisation du TGF-bêta, ainsi qu'une maladie sélectionnée dans le groupe constitué par : la fibrose tissulaire, telle que la fibrose pulmonaire, notamment la fibrose pulmonaire idiopathique; la fibrose du foie, notamment la cirrhose et l'hépatite chronique; la polyarthrite rhumatoïde; les troubles oculaires; la fibrose de la peau, notamment les chéloïdes; la maladie de Dupuytren; la fibrose rénale, telle que la néphrite et la néphrosclérose; la cicatrisation; la réduction des cicatrices; et une affection vasculaire, telle que la resténose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)